Guardant Health wins at Healthcare Asia Medtech Awards 2026

The ShieldTM Multi-cancer Detection (MCD) test offers screening for 10 types of cancers with just a blood draw. 

Guardant Health Pte Ltd won Oncology Product Innovation of the Year in the Healthcare Asia  Medtech Awards 2026 for the Shield MCD test. 

The Shield MCD test detects multiple cancer types from DNA shed in the blood. The Shield  MCD test is a methylation-based blood test for the detection of multiple cancer types, including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer in individuals aged 45 years or older without a known diagnosis of cancer, and it is not indicated for use in pregnant women. In the United States, the Shield MCD test has received Breakthrough Device Designation from the U.S. Food and Drug Administration  (FDA). 

Data from the 2025 American Association for Cancer Research annual meeting showed that the  Shield MCD test achieved 99% overall specificity and 74% sensitivity across six aggressive cancers, including esophageal-gastric, hepatocellular, lung, ovarian, and pancreatic. The test also predicted cancer signals of origin with 93% accuracy.

The FDA Breakthrough Device designation referenced eight cancer types — bladder, colorectal,  esophageal, gastric, liver, lung, ovarian, and pancreatic cancer — in individuals aged 45 or older who are at typical average risk for cancer, as defined by the agency at the time of designation.  This designation does not imply FDA approval, clearance, or endorsement of the device’s safety or effectiveness.

The Healthcare Asia Medtech Awards honours the most exemplary medtech companies across Asia. It serves as a platform for organisations to showcase their pioneering medical devices,  life-saving software, or top-notch healthcare solutions, amongst other innovations. 

Laboratory and test information: The Shield MCD is a laboratory-developed test that was developed and whose performance characteristics were determined by Guardant Health, Inc. This test may be used for clinical purposes and should not be regarded as investigational or for research only. Guardant Health’s clinical laboratory is certified under the Clinical Laboratory  Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing and accredited by the College of American Pathologists (CAP). This test is not part of the Shield IVD and has not been cleared or approved by the FDA. For Export Use Only. Not for sale or use in the United States.

The Healthcare Asia Medtech Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be acclaimed for your organisation's initiatives and contribution to enhancing the industry's overall performance, please contact Julie Anne Nuñez-Difuntorum at [email protected].